David Walde
About
David Walde is a scholar working on Oncology, Surgery and Physiology.
According to data from OpenAlex, David Walde has authored 22 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 6 papers in Surgery and 5 papers in Physiology. Recurrent topics in David Walde's work include Cancer Treatment and Pharmacology (6 papers), Nausea and vomiting management (5 papers) and Neuroendocrine Tumor Research Advances (4 papers). David Walde is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Nausea and vomiting management (5 papers) and Neuroendocrine Tumor Research Advances (4 papers). David Walde collaborates with scholars based in Canada, United States and New Zealand. David Walde's co-authors include Keyue Ding, Malcolm J. Moore, P. Murawa, Steven Gallinger, Robert A. Wolff, Daniel de Castro, David Goldstein, Gary M. Clark, J. Randolph Hecht and Robert Lim and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.
In The Last Decade
David Walde
22 papers receiving 4.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| David Walde Canada | 16 | 3.7k | 1.4k | 1.0k | 1.0k | 901 | 22 | 4.8k | ||
| Markus Borner Switzerland | 43 | 3.0k 0.8× | 1.8k 1.3× | 847 0.8× | 1.8k 1.7× | 1.1k 1.3× | 126 | 5.6k | ||
| Laëtitia Dahan France | 36 | 3.5k 0.9× | 1.7k 1.2× | 620 0.6× | 855 0.8× | 1.5k 1.6× | 144 | 5.3k | ||
| Jorge Barriuso United Kingdom | 34 | 2.4k 0.6× | 908 0.6× | 815 0.8× | 979 1.0× | 1.1k 1.2× | 137 | 4.0k | ||
| Connie Stephens United States | 7 | 3.9k 1.1× | 1.1k 0.8× | 1.4k 1.4× | 1.0k 1.0× | 957 1.1× | 9 | 4.9k | ||
| Henry Q. Xiong United States | 18 | 2.8k 0.8× | 1.3k 0.9× | 1.0k 1.0× | 1.2k 1.2× | 801 0.9× | 39 | 4.3k | ||
| Miao‐Zhen Qiu China | 38 | 2.5k 0.7× | 1.6k 1.1× | 1.3k 1.2× | 1.6k 1.6× | 1.1k 1.2× | 165 | 4.9k | ||
| Young Suk Park South Korea | 41 | 4.0k 1.1× | 2.3k 1.6× | 1.1k 1.1× | 1.3k 1.3× | 1.9k 2.1× | 227 | 6.3k | ||
| Hagen F. Kennecke Canada | 33 | 3.6k 1.0× | 1.4k 1.0× | 1.9k 1.8× | 1.4k 1.3× | 686 0.8× | 156 | 5.5k | ||
| P. Murawa Poland | 16 | 3.0k 0.8× | 1.2k 0.8× | 1.1k 1.0× | 890 0.9× | 770 0.9× | 47 | 4.1k | ||
| Denis Péré-Vergé France | 6 | 5.0k 1.3× | 1.5k 1.1× | 1.8k 1.7× | 964 0.9× | 1.3k 1.4× | 11 | 5.6k |
Countries citing papers authored by David Walde
Since
Specialization
Citations
This map shows the geographic impact of David Walde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Walde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Walde more than expected).
Fields of papers citing papers by David Walde
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by David Walde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Walde. The network helps show where David Walde may publish in the future.
Co-authorship network of co-authors of David Walde
This figure shows the co-authorship network connecting the top 25 collaborators of David Walde. A scholar is included among the top collaborators of David Walde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Walde. David Walde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Moore, Malcolm J., David Goldstein, John Hamm, et al.. (2023). Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology. 41(30). 4714–4720.
2.
Hagen, Neil A., Bernard Lapointe, May Ong-Lam, et al.. (2011). A Multicentre Open-Label Safety and Efficacy Study of Tetrodotoxin for Cancer Pain. Current Oncology. 18(3). 109–116.
3.
Pritchard, Kathleen I., Lois E. Shepherd, Judith‐Anne W. Chapman, et al.. (2011). Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14. Journal of Clinical Oncology. 29(29). 3869–3876.
4.
Renouf, Daniel J., Malcolm J. Moore, David W. Hedley, et al.. (2010). A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. Investigational New Drugs. 30(2). 779–786.
5.
Goodwin, Rachel, Keyue Ding, Lesley Seymour, et al.. (2010). Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. Annals of Oncology. 21(11). 2220–2226.
6.
Goss, Glenwood, Andrew Arnold, Frances A. Shepherd, et al.. (2009). Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study. Journal of Clinical Oncology. 28(1). 49–55.
7.
Hagen, Neil A., Patrick du Souich, Bernard Lapointe, et al.. (2008). Tetrodotoxin for Moderate to Severe Cancer Pain: A Randomized, Double Blind, Parallel Design Multicenter Study. Journal of Pain and Symptom Management. 35(4). 420–429.
8.
Findlay, B., Katia Tonkin, Michael Crump, et al.. (2007). A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes. Annals of Oncology. 18(10). 1646–1651.
9.
Moore, Malcolm J., David Goldstein, John Hamm, et al.. (2007). Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology. 25(15). 1960–1966.
10.
Shustik, Chaim, Andrew R. Belch, Sue Robinson, et al.. (2006). A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. British Journal of Haematology. 136(2). 203–211.
11.
Hoff, Paulo M., Rafat Ansari, Gerald Batist, et al.. (2001). Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study. Journal of Clinical Oncology. 19(8). 2282–2292.
12.
Goss, Paul E., David Walde, R. De Coster, Christine Langenaeken, & J. Bruynseels. (1999). Rivizor – A New Third-Generation Aromatase Inhibitor for the Treatment of Advanced Breast Cancer after Tamoxifen Failure. Oncology. 56(2). 114–121.
13.
Murray, Nevin, Robert B. Livingston, Frances A. Shepherd, et al.. (1999). Randomized Study of CODE Versus Alternating CAV/EP for Extensive-Stage Small-Cell Lung Cancer: An Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. Journal of Clinical Oncology. 17(8). 2300–2300.
14.
Latreille, Jean, Joseph L. Pater, D. Johnston, et al.. (1998). Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group.. Journal of Clinical Oncology. 16(3). 1174–1178.
15.
Pater, Joseph L., W. Lofters, Benny Zee, et al.. (1997). The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Annals of Oncology. 8(2). 181–185.
16.
Lofters, W., Joseph L. Pater, Benny Zee, et al.. (1997). Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.. Journal of Clinical Oncology. 15(8). 2966–2973.
17.
Latreille, Jean, Francis Laberge, Paul Hoskins, et al.. (1995). Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy. Supportive Care in Cancer. 3(5). 307–312.
18.
Latreille, Jean, Francis Laberge, Paul Hoskins, et al.. (1993). Dexamethasone (DEX) improves the efficacy of granisetron (GRAN) in the first 24 hours following high dose cisplatin (HDCP) chemotherapy. European Journal of Cancer. 29. S208–S208.
19.
Skillings, Jamey, C. Cripps, E. Eisenhauer, et al.. (1991). A phase II study of menogaril in low-grade non-Hodgkin's lymphoma. Investigational New Drugs. 9(1). 79–82.
20.
Whelton, M. J., David Walde, & C. W. H. Havard. (1971). Hyperosmolar Non-ketotic Diabetic Coma: With Particular Reference to Vascular Complications. BMJ. 1(5740). 85–86.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Markus Borner Breakdown of academic impact, for papers by Laëtitia Dahan Breakdown of academic impact, for papers by Jorge Barriuso Breakdown of academic impact, for papers by Connie Stephens Breakdown of academic impact, for papers by Henry Q. Xiong Breakdown of academic impact, for papers by Miao‐Zhen Qiu Breakdown of academic impact, for papers by Young Suk Park Breakdown of academic impact, for papers by Hagen F. Kennecke Breakdown of academic impact, for papers by P. Murawa Breakdown of academic impact, for papers by Denis Péré-Vergé